You and Respert are exactly right, IMO. I can't imagine having much to add; except to say that since Dr Jay is an honorable man, he wouldn't back away from doing something he'd effectively promised to do unless he had a damn solid reason he could share with us shareholders later.

So for me the only question is who is the suitor? Madrigal? Their market cap is only 7 billion, so that would involve a licensing deal at best. If it's somebody with deeper pockets and a broader sweep in mind, maybe GSK? They had a GLP-1 agonist (Tanzeum) which they withdrew from the market back in 2017 due to it's being less effective than Ozempic and Mounjaro, maybe this gets them back in that market plus HIV and all the other indications on Ohm's list. Plus, Max Detaillade is still a GSK guy as far as I'm concerned.

Who knows, but big things are in store, it's a great time to be long CYDY.